Flotte T
Mol Ther. 2013; 21(11):1976-81.
PMID: 24201212
PMC: 3831048.
DOI: 10.1038/mt.2013.226.
Musatov S, Roberts J, Pfaff D, Kaplitt M
J Virol. 2002; 76(24):12792-802.
PMID: 12438604
PMC: 136660.
DOI: 10.1128/jvi.76.24.12792-12802.2002.
Wang X, Khuntirat B, Qing K, Ponnazhagan S, Kube D, Zhou S
J Virol. 1998; 72(7):5472-80.
PMID: 9621003
PMC: 110186.
DOI: 10.1128/JVI.72.7.5472-5480.1998.
Smith R, Kotin R
J Virol. 1998; 72(6):4874-81.
PMID: 9573254
PMC: 110039.
DOI: 10.1128/JVI.72.6.4874-4881.1998.
Wang X, Srivastava A
J Virol. 1998; 72(6):4811-8.
PMID: 9573246
PMC: 110022.
DOI: 10.1128/JVI.72.6.4811-4818.1998.
Recombinant adeno-associated virus type 2 replication and packaging is entirely supported by a herpes simplex virus type 1 amplicon expressing Rep and Cap.
Conway J, Zolotukhin S, Muzyczka N, Hayward G, Byrne B
J Virol. 1997; 71(11):8780-9.
PMID: 9343238
PMC: 192344.
DOI: 10.1128/JVI.71.11.8780-8789.1997.
The Rep78 gene product of adeno-associated virus (AAV) self-associates to form a hexameric complex in the presence of AAV ori sequences.
Smith R, Spano A, Kotin R
J Virol. 1997; 71(6):4461-71.
PMID: 9151837
PMC: 191665.
DOI: 10.1128/JVI.71.6.4461-4471.1997.
Adeno-associated virus type 2 DNA replication in vivo: mutation analyses of the D sequence in viral inverted terminal repeats.
Wang X, Qing K, Ponnazhagan S, Srivastava A
J Virol. 1997; 71(4):3077-82.
PMID: 9060669
PMC: 191438.
DOI: 10.1128/JVI.71.4.3077-3082.1997.
A novel terminal resolution-like site in the adeno-associated virus type 2 genome.
Wang X, Srivastava A
J Virol. 1997; 71(2):1140-6.
PMID: 8995635
PMC: 191166.
DOI: 10.1128/JVI.71.2.1140-1146.1997.
Rescue and replication of adeno-associated virus type 2 as well as vector DNA sequences from recombinant plasmids containing deletions in the viral inverted terminal repeats: selective encapsidation of viral genomes in progeny virions.
Wang X, Ponnazhagan S, Srivastava A
J Virol. 1996; 70(3):1668-77.
PMID: 8627687
PMC: 189990.
DOI: 10.1128/JVI.70.3.1668-1677.1996.
Biologically active Rep proteins of adeno-associated virus type 2 produced as fusion proteins in Escherichia coli.
Chiorini J, Weitzman M, Owens R, Urcelay E, Safer B, Kotin R
J Virol. 1994; 68(2):797-804.
PMID: 8289383
PMC: 236516.
DOI: 10.1128/JVI.68.2.797-804.1994.
Sequence requirements for stable binding and function of Rep68 on the adeno-associated virus type 2 inverted terminal repeats.
Chiorini J, Wiener S, Owens R, Kyostio S, Kotin R, Safer B
J Virol. 1994; 68(11):7448-57.
PMID: 7933128
PMC: 237187.
DOI: 10.1128/JVI.68.11.7448-7457.1994.
Expression from the adeno-associated virus p5 and p19 promoters is negatively regulated in trans by the rep protein.
Beaton A, Palumbo P, Berns K
J Virol. 1989; 63(10):4450-4.
PMID: 2550677
PMC: 251068.
DOI: 10.1128/JVI.63.10.4450-4454.1989.
Both excision and replication of cloned autonomous parvovirus DNA require the NS1 (rep) protein.
Rhode 3rd S
J Virol. 1989; 63(10):4249-56.
PMID: 2528644
PMC: 251039.
DOI: 10.1128/JVI.63.10.4249-4256.1989.
Mutation of lysine 405 to serine in the parvovirus H-1 NS1 abolishes its functions for viral DNA replication, late promoter trans activation, and cytotoxicity.
Li X, Rhode 3rd S
J Virol. 1990; 64(10):4654-60.
PMID: 2144594
PMC: 247949.
DOI: 10.1128/JVI.64.10.4654-4660.1990.
Origin of adeno-associated virus DNA replication is a target of carcinogen-inducible DNA amplification.
Yalkinoglu A, Zentgraf H, Hubscher U
J Virol. 1991; 65(6):3175-84.
PMID: 2033669
PMC: 240974.
DOI: 10.1128/JVI.65.6.3175-3184.1991.
Induction of differentiation-associated changes in established human cells by infection with adeno-associated virus type 2.
zur Hausen H, Schlehofer J
J Virol. 1992; 66(7):4191-200.
PMID: 1318400
PMC: 241222.
DOI: 10.1128/JVI.66.7.4191-4200.1992.
